ABUS
Arbutus Biopharma Corp
NASDAQ: ABUS · HEALTHCARE · BIOTECHNOLOGY
$4.32
+0.70% today
Updated 2026-10-28
Market cap
$646.82M
P/E ratio
5.34
P/S ratio
3.56x
EPS (TTM)
$0.79
Dividend yield
—
52W range
$4 – $5
Volume
5.9M
Arbutus Biopharma Corp (ABUS) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$4.32
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 15.29% (capped 20%) · P/E: 5.34x (capped 25x) · Margin: 84.20%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.